Skip to main content
SpringerLink
Log in

Targeted Therapy in the Treatment of Orbital and Periorbital Malignancies

  • Chapter
Oculoplastics and Orbit

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

  • 1737 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bariteh F, Kurzrock R, Johnson FM (2008) Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 6:3460–3462

    Article  Google Scholar 

  2. Bernstein ID, Tam MR, Nowinski RC (1980) Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen. Science 207(4426):68–71

    Article  PubMed  CAS  Google Scholar 

  3. Bubien JK, Zhou LJ, Bell PD, et al (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 121(5):1121–1132

    Article  PubMed  CAS  Google Scholar 

  4. Coiffier B, Lepage E, Briere J, et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  PubMed  CAS  Google Scholar 

  5. Costa RL (2009) Targeted therapy: comprehensive review. Am J Hosp Palliat Care (Epub ahead of print 19 Feb)

    Google Scholar 

  6. Demetri GD, von Mehren M, Blanke CD, et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

    Article  PubMed  CAS  Google Scholar 

  7. Dogan SS, Esmaeli B (2009) Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. Hematol Oncol Clin North Am 23:109–114

    Article  PubMed  Google Scholar 

  8. Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3–7

    Article  PubMed  CAS  Google Scholar 

  9. Druker BJ, Talpaz M, Resta DJ, et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

    Article  PubMed  CAS  Google Scholar 

  10. Erwin WD, Esmaeli B (2009) Estimation of yttrium-90 Zevalin tumor absorbed dose in ocular adnexal lymphoma using quantitative indium-111 Zevalin radionuclide imaging. Nucl Med Commun 30 (9):681–686

    Article  PubMed  Google Scholar 

  11. Esmaeli B, Murray JL, Ahmadi MA, et al (2002) Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit. Arch Ophthalmol 120(9):1225–1227

    Article  PubMed  Google Scholar 

  12. Esmaeli B, Prieto VG, Butler CE, et al (2002) Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95(4):881–887

    Article  PubMed  Google Scholar 

  13. Esmaeli B, Prieto VG, Gonnering R, et al (2004) Growth factor receptor expression in orbital lymphangioma: possible therapeutic implications. Orbit 23(4):263–269

    Article  PubMed  Google Scholar 

  14. Esmaeli B, McLaughlin P, Pro B, et al (2009) Prospective trial of targeted radioimmunotherapy with Y-90 ibritu-momab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol (Epub ahead of print)

    Google Scholar 

  15. Feugier P, Van Hoof A, Sebban C, et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117–4126

    Article  PubMed  CAS  Google Scholar 

  16. Fisher RI, Gaynor ER, Dahlberg S, et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002–1006

    Article  PubMed  CAS  Google Scholar 

  17. Gold KA, Lee HY, Kim ES (2009) Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115(5):922–935

    Article  PubMed  CAS  Google Scholar 

  18. Ho HH, Savar A, Samaniego F, Manning J, Kasyan A,Pro B, Esmaeli B (2009) Treatment of benign lymphoid hyperpla-sia of the orbit with rituximab. Ophthal Plast Reconstr Surg (in press)

    Google Scholar 

  19. Ivan D, Prieto VG, Esmaeli B, Wistuba II,Tang X, Lazar AJF (2009) Epidermal growth factor receptor (EGFR) expression in ocular and extraocular sebaceous gland carcinomas. J Cutan Pathol (July 2009), Epub ahead of print

    Google Scholar 

  20. Knox SJ, Goris ML, Trisler K, et al (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2(3):457–470

    PubMed  CAS  Google Scholar 

  21. Mac Manus M P, Hoppe RT. (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282–1290

    CAS  Google Scholar 

  22. Normanno N, De Luca A, Bianco C, et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1):2–16

    Article  PubMed  CAS  Google Scholar 

  23. On AV, Hirschbein MJ, Williams HJ, et al (2006) CyberKnife radiosurgery and rituximab in the successful management of sclerosing idiopathic orbital inflammatory disease. Ophthal Plast Reconstr Surg 22(5):395–397

    Article  PubMed  Google Scholar 

  24. Reff ME, Carner K, Chambers KS, et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2):435–445

    PubMed  CAS  Google Scholar 

  25. Salvi M, Vannucchi G, Campi I, et al (2007) Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156(1):33–40

    Article  PubMed  CAS  Google Scholar 

  26. Shepler TR, Prieto VG, Diba R, et al (2006) Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma. Ophthal Plast Reconstr Surg 22(2):113–115

    Article  PubMed  Google Scholar 

  27. Shome D, Esmaeli B (2008) Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa. Curr Opin Ophthalmol 19(5):414–421

    Article  PubMed  Google Scholar 

  28. Sullivan TJ, Grimes D, Bunce I (2004) Monoclonal antibody treatment of orbital lymphoma. Ophthal Plast Reconstr Surg 20(2):103–106

    Article  PubMed  Google Scholar 

  29. Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15(9):450–454

    Article  PubMed  CAS  Google Scholar 

  30. Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K (2005) Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (“Iressa,” ZD1839) in phase I and II clinical trials. Eye 19:729–738

    Article  PubMed  CAS  Google Scholar 

  31. Vigna E, Lucia E, Gentile M, et al (2008) PDGFRalpha/ FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. Cancer Chemother Pharmacol 61(4):713–716

    Article  PubMed  Google Scholar 

  32. Witzig TE, Gordon LI, Cabanillas F, et al (2002) Randomized controlled trial of yttrium-90-labeled ibritu-momab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20(10):2453–2463

    Article  PubMed  CAS  Google Scholar 

  33. Witzig TE, Inwards DJ, Habermann TM, et al (2007) Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. Mayo Clin Proc 82(6):692–699

    PubMed  Google Scholar 

  34. Esmaeli B, Diba R, Ahmadi MA, et al (2004) Periorbital edema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye 18:760–762

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Head and Neck Surgery, Section of Ophthalmology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Aaron Savar

  2. Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1445, Houston, Texas, 77030, USA

    Bita Esmaeli

Authors
  1. Aaron Savar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bita Esmaeli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, University of Rostock, Doberaner Straße 140, 18055, Rostock, Germany

    Rudolf F. Guthoff (Professor of Ophthalmology) (Professor of Ophthalmology)

  2. Children's Hospital of Philadelphia, R. D. Wood Ambulatory Care Building Division of Ophthalmology, 34th Street Civic Center Blvd., Philadelphia, PA, 19104, USA

    James A. Katowitz (Professor of Ophthalmology) (Professor of Ophthalmology)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Savar, A., Esmaeli, B. (2010). Targeted Therapy in the Treatment of Orbital and Periorbital Malignancies. In: Guthoff, R.F., Katowitz, J.A. (eds) Oculoplastics and Orbit. Essentials in Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85542-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-85542-2_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-85541-5

  • Online ISBN: 978-3-540-85542-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation